H. Lundbeck A/S’ antibody-based migraine therapy, Vyepti (eptinezumab-jjmr), which just received FDA approval as the first and only intravenous preventive treatment for adults, enters a market forecast to grow to $7 billion by 2027. While some analysts placed Vyepti’s earnings potential at about $800 million annually, the drug itself is positioned to become a possible blockbuster, earning $1 billion annually. Read More
NGM Biopharmaceuticals Inc. wowed investors with positive preliminary top-line results from the 24-week double-blind, randomized, placebo-controlled fourth cohort of an adaptive phase II study testing aldafermin in nonalcoholic steatohepatitis (NASH). Read More
Investors continue to keep a close eye on the progress of companies involved in developing medicines targeting the central nervous system and, in the main, their reaction has been generally positive. The BioWorld Neurological Diseases index, a price-weighted index of public biopharmaceutical companies that are focused on developing therapies to treat neurological diseases, closed the year up over 16% and after, a dip in January, is now tracking up more than 12% by market close on Friday Feb. 21, well ahead of the general markets for the same period. Read More
LONDON – The COVID-19 outbreak appears to be sliding toward pandemic status, with the virus spreading to four more countries and confirmed cases and deaths mounting in infection hotspots in Italy, Iran and South Korea. Read More
Paris-based Sanofi SA, responding to increasing medicine shortages and drugmakers' heavy reliance on active pharmaceutical ingredients (APIs) sourced from Asia, said it plans to create a major new API manufacturer headquartered in France. Read More
Although the World Health Organization (WHO) acknowledged COVID-19 is spreading, they say it has not yet reached pandemic disease status. The statement did little to comfort the nerves of investors Feb. 24 as they exited global markets big time in the wake of an eruption of new infections in Italy, Iran and South Korea. Read More
Biopharmas raising money in public or private financings, including: Acerus, Adma, Aeterna Zentaris, Alimera, Enlivex, Fortress, Genprex, Outlook. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aldeyra, Aura, BMS, Cytomx, Kadmon, NGM, Nymox, Oncoimmune, Pandion, Proteostasis, Sojournix, United. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascentage, Contrafect, Deka, Enochian, Genmab, Glaxosmithkline, Lundbeck, Lilly, Novartis, Seqirus, Takeda, Tetra, United. Read More
